Portola Pharmaceuticals, LLC
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$16.7M
Doctors Paid
11,269
Transactions
25,475
2020 Total
$4.3M
Payment Breakdown by Category
Research$10.0M (59.9%)
Food & Beverage$821,424 (4.9%)
Consulting$688,271 (4.1%)
Travel$557,349 (3.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $10.0M | 2,057 | 59.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.6M | 705 | 15.4% |
| Honoraria | $1.2M | 630 | 7.4% |
| Food and Beverage | $821,424 | 20,121 | 4.9% |
| Consulting Fee | $688,271 | 64 | 4.1% |
| Grant | $599,430 | 4 | 3.6% |
| Travel and Lodging | $557,349 | 1,623 | 3.3% |
| Space rental or facility fees (teaching hospital only) | $228,232 | 156 | 1.4% |
| Education | $2,378 | 114 | 0.0% |
| Entertainment | $209.80 | 1 | 0.0% |
Payments by Type
Research
$10.0M
2,057 transactions
General
$6.7M
23,418 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| 13-601 | $6.0M | 0 | 638 |
| 14-505 | $1.2M | 0 | 436 |
| A PHASE 4 RANDOMIZED CLINICAL TRIAL OF ANDEXANET ALFA [ANDEXANET ALFA FOR INJECTION] IN ACUTE INTRACRANIAL HEMORRHAGE IN PATIENTS RECEIVING AN ORAL FA | $683,141 | 0 | 227 |
| APEX TRIAL: EXECUTIVE COMMITTEE AGREEMENT | $562,500 | 0 | 1 |
| 17-022 | $549,459 | 0 | 6 |
| RECOMBINANT FACTOR XA INHIBITOR ANTIDOTE | $390,878 | 0 | 722 |
| DCRI #7488 BRAVO (BETRIXABAN) REGISTRY | $250,000 | 0 | 1 |
| APEX Publications | $178,605 | 1 | 1 |
| PROSPECTIVE OPEN-LABEL STUDY OF ANDEXANET ALFA IN PATIENTS RECEIVING FACTOR XA INHIBITOR WHO REQUIRE URGENT SURGERY (ANNEXA-S) | $41,650 | 0 | 16 |
| ADEXANET STUDY - PERFUSE STUDY GROUP - EDUCATIONAL WEBSITE, Q4, YEAR 3 | $19,500 | 0 | 1 |
| ANNEXA - 4 | $15,389 | 0 | 2 |
| 16-510 USUAL CARE COHORT | $10,000 | 0 | 1 |
| A PROSPECTIVE COHORT STUDY OF PATIENT RECEIVING A FACTOR XA INHIBITOR WHO HAVE ACUTE MAJOR BLEEDING AN RECEIVE USUAL CARE | $5,355 | 0 | 1 |
| THE RECTOR AND VISITORS OF THE UNIVERSITY OF VIRGINIA | $3,000 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2018 |
|---|---|---|---|---|
| Charles Gibson, M.d, M.D | Interventional Cardiology | Boston, MA | $464,347 | $0 |
| Dr. Fariborz Rezai, M.d, M.D | Internal Medicine | Livingston, NJ | $203,795 | $0 |
| Dr. Nirav Patel, M.d, M.D | Neurology | Los Alamitos, CA | $196,155 | $0 |
| Robert Takla, Md, MD | Emergency Medicine | Southfield, MI | $178,865 | $0 |
| Mauricio Concha, Md, MD | Neurology | Sarasota, FL | $162,280 | $0 |
| Charles Homcy, M.d, M.D | General Acute Care Hospital | San Francisco, CA | $129,000 | $0 |
| Bruce Friedman, M.d, M.D | Critical Care Medicine | Augusta, GA | $113,854 | $0 |
| John Cornell, Md, MD | Family Medicine | Huntington, WV | $103,155 | $0 |
| Hameed Ali, D. O, D. O | Internal Medicine | Temple, TX | $92,064 | $0 |
| Mark Alberts, Md, MD | Neurology | Dallas, TX | $79,400 | $0 |
| Dr. Steven Deitelzweig, Md, MD | Internal Medicine | New Orleans, LA | $75,787 | $0 |
| Dr. Gregory Fermann, Md, MD | Emergency Medicine | Cincinnati, OH | $71,328 | $0 |
| Niels Martin, Md, MD | Surgery | Philadelphia, PA | $66,833 | $0 |
| Dr. Nedaa Skeik, Md, MD | Internal Medicine | Minneapolis, MN | $64,313 | $0 |
| Alan Jacobson, M.d, M.D | Cardiovascular Disease | Loma Linda, CA | $59,204 | $0 |
| Rondel Albarado, M.d, M.D | Surgical Critical Care | Houston, TX | $56,624 | $0 |
| Dr. Glenn Michelson, M.d, M.D | Hematology & Oncology | Berkeley, CA | $50,200 | $0 |
| Dr. Fred Rincon, M.d, M.D | Critical Care Medicine | Camden, NJ | $48,979 | $0 |
| Dr. Kelly Larkin, M.d, M.D | Emergency Medicine | Houston, TX | $48,022 | $0 |
| Dr. Arthur Weiss, Md, MD | Internal Medicine | San Francisco, CA | $47,721 | $0 |
| Dr. Jeffrey Deitch, Do, DO | Family Medicine | Sterling Heights, MI | $46,165 | $0 |
| Dr. Melissa Taylor, Md, MD | Anesthesiology | Grand Rapids, MI | $45,860 | $0 |
| Natalie Kreitzer, M.d, M.D | Emergency Medicine | Cincinnati, OH | $45,246 | $0 |
| David Burt, M.d, M.D | Emergency Medicine | Charlottesville, VA | $42,292 | $0 |
| Heather Davis, Md, MD | Critical Care Medicine | Claremont, CA | $40,695 | $0 |
Ad
Top Products
- ANDEXXA $5.7M
- BEVYXXA $4.0M
Associated Products (4)
- ANDEXXA $11.5M
- BEVYXXA $4.0M
- CURDULATINIB $2.4M
- Bevyxxa $437,227
Payment Categories
- Food & Beverage $821,424
- Consulting $688,271
- Travel & Lodging $557,349
- Research $10.0M
About Portola Pharmaceuticals, LLC
Portola Pharmaceuticals, LLC has made $16.7M in payments to 11,269 healthcare providers, recorded across 25,475 transactions in the CMS Open Payments database. In 2020, the company paid $4.3M. The top product by payment volume is ANDEXXA ($5.7M).
Payments were distributed across 169 medical specialties. The top specialty by payment amount is Internal Medicine ($1.1M to 2,341 doctors).
Payment categories include: Food & Beverage ($821,424), Consulting ($688,271), Research ($10.0M), Travel & Lodging ($557,349).
Portola Pharmaceuticals, LLC is associated with 4 products in the CMS Open Payments database, including ANDEXXA, BEVYXXA, and CURDULATINIB.